viru
hav
proteinas
picornavir
cystein
proteinas
essenti
cleavag
initi
synthes
viral
polyprotein
precursor
matur
fragment
therefor
requir
viral
replic
vivo
sinc
enzym
gener
recogn
peptid
substrat
lglutamin
p
site
four
type
analogu
azaglutamin
residu
chemic
synthes
hydrazoonitrophenylsulfenamid
eg
frameshift
hydrazoonitrophenylsulfenamid
b
eg
azaglutamin
sulfonamid
c
eg
haloacetyl
azaglutamin
analogu
test
compound
inhibit
hav
proteinas
employ
mutant
nonessenti
surfac
cystein
replac
serin
display
ident
catalyt
paramet
wildtyp
enzym
sulfenamid
type
show
inhibit
sulfenamid
type
b
ic
ca
mm
gave
timedepend
inactiv
enzym
due
bond
format
activ
site
cystein
thiol
demonstr
electrospray
mass
spectrometri
sulfonamid
type
c
weak
competit
inhibitor
ic
approxim
mm
haloacetyl
azaglutamin
analogu
timedepend
irrevers
inactiv
hav
proteinas
rate
constant
k
ob
respect
shown
alkyl
activ
site
thiol
famili
picornavirus
known
member
divid
six
genera
contain
pathogen
polioviru
human
rhinoviru
hrv
encephalornyocard
viru
foot
mouth
diseas
viru
hepat
viru
hav
virus
possess
posit
singlestrand
rna
genom
whose
translat
mammalian
cell
produc
larg
protein
product
coand
posttransl
process
initi
polyprotein
reli
highli
organ
cleavag
viral
cystein
proteinas
attract
target
develop
therapeut
agent
among
cystein
proteinas
subject
extens
structur
investig
crystal
structur
report
hav
hrv
polioviru
protein
analog
proteinas
also
detect
human
avian
coronavirus
essenti
viral
enzym
especi
appeal
target
pharmaceut
intervent
uniqu
activ
site
geometri
make
highli
choic
substrat
cleavag
site
absent
noninfect
mammalian
cell
addit
activ
site
residu
appear
rel
invari
rhinoviru
larg
number
serotyp
make
vaccin
develop
dicult
structur
proteinas
topolog
resembl
two
domain
bbarrel
fold
chymotrypsinlik
serin
proteinas
activ
site
cystein
hav
close
proxim
histidin
residu
hav
act
gener
base
form
nucleophil
thiolat
anion
substrat
recognit
analog
chymotrypsin
famili
believ
involv
antiparallel
bind
backbon
peptid
proteinas
interact
side
chain
enzym
sever
key
subsit
hydrogenbond
carbonyl
oxygen
side
chain
p
glutamin
substrat
peptid
inhibitor
histidin
subsit
hav
probabl
one
key
recognit
event
wild
type
hav
amino
acid
molecular
weight
kilodalton
exist
activ
monom
peptid
substrat
mimick
junction
larg
precursor
polyprotein
k
cat
enzym
typic
k
mm
ph
search
therapeut
lead
enzym
inhibit
studi
hav
hrv
protein
employ
larg
varieti
compound
includ
peptid
aldehyd
keton
blactam
isatin
homophthalimid
vinylog
ester
sulfon
halomethyl
carbonyl
compound
compound
show
vitro
antivir
activ
cell
cultur
toxic
problem
substanc
gener
reactiv
thiol
present
studi
examin
number
sulfurcontain
azaglutamin
deriv
potenti
inhibitor
hav
proteinas
incorpor
hydrazino
function
peptid
backbon
azapeptid
wellestablish
gener
proteinas
inhibitor
includ
cystein
proteinas
recent
analogu
shown
act
activ
site
titrant
cystein
proteinas
certain
symmetr
bishydrazid
extrem
potent
nanomolar
inhibitor
cathepsin
k
cystein
proteinas
involv
boneremodel
one
studi
hrv
proteinas
nbromoacetyl
azaglutamin
dipeptid
analogu
shown
ic
approxim
nm
timedepend
irrevers
inactiv
k
inact
k
valu
howev
case
inhibitori
activ
depend
highli
reactiv
bromoacetyl
moieti
like
react
varieti
thiol
present
mammalian
cell
amid
charact
sulfenamid
use
aryl
sulfenamid
amino
acid
protect
group
remov
thiol
acid
condit
scheme
suggest
function
could
display
sucient
low
intrins
reactiv
still
form
activ
site
thiol
hav
cystein
proteinas
thu
sulfenamid
azaglutamin
analogu
type
b
well
sulfonamid
deriv
c
synthes
investig
inhibit
enzym
although
sulfonamid
c
would
expect
react
activ
site
cystein
potenti
bind
activ
site
residu
also
provid
new
sulfurcontain
aza
analogu
motif
investig
haloacetyl
azaglutamin
analogu
also
prepar
comparison
case
side
chain
amid
function
bear
two
methyl
sinc
group
wellaccept
hav
enzym
hinder
interact
possibl
reactiv
intermedi
especi
p
carbonyl
site
result
discuss
synthesi
test
peptidosulfonamid
c
examin
structur
c
indic
condens
known
abromoketon
anion
deriv
sulfonamid
balanin
dimethylamid
use
procedur
jone
would
aord
dipeptid
analogu
respect
scheme
requir
sulfonamid
readili
avail
deprotect
nbocbalanin
dimethylamid
follow
reaction
appropri
sulfonyl
chlorid
expect
condens
bromoketon
proce
readili
follow
hydrogenolysi
remov
cbz
group
quantit
yield
form
correspond
amino
compound
studi
sequenc
recognit
hav
proteinas
use
model
peptid
suggest
p
residu
hydrophob
amino
acid
lleucin
p
p
residu
lalanin
idea
support
scheme
inhibit
enzym
nanomolar
level
aldehyd
peptid
analogu
sequenc
thu
coupl
nacetyllleucinyllalanin
proce
readili
ethyl
chloroform
gener
target
tetrapeptid
azaglutamin
sulfonamid
deriv
assay
sulfonamid
inhibit
hav
proteinas
employ
mutant
nonessenti
surfac
cystein
replac
serin
display
catalyt
paramet
indistinguish
wildtyp
enzym
compound
weak
competit
inhibitor
potent
ic
valu
mm
lower
k
ideal
hexapeptid
substrat
mm
potent
enough
warrant
extens
studi
view
nanomolar
inhibit
achiev
peptid
aldehyd
uoromethyl
keton
sulfonamid
ic
valu
mm
synthesi
potenti
inhibitor
structur
framework
michael
addit
hydrazin
n
ndimethylacrylamid
follow
protect
nucleophil
secondari
nitrogen
benzyl
chloroform
gener
along
correspond
bisacyl
product
scheme
coupl
free
primari
nitrogen
tripeptid
nacetyllleucinyllalanyllalanin
proce
smoothli
give
hydrogenolyt
deprotect
liber
alkyl
nitrogen
immedi
react
onitrosulfenyl
chlorid
aord
target
sulfenamid
transform
becam
clear
azaglutamin
seri
compound
amid
charact
one
nitrogen
prone
facil
decomposit
protect
basic
nitrogen
quickli
possibl
disappointingli
show
inhibit
ic
mm
hav
proteinas
despit
presenc
p
p
backbon
detect
reaction
inhibitor
level
competit
bind
activ
site
also
low
presum
aromat
sulfenamid
moieti
bulki
easili
accommod
enzym
site
bind
p
h
substrat
residu
sulfenamid
prepar
wherein
onitrophenyl
group
replac
methyl
compound
display
poor
stabil
especi
water
pursu
prepar
structur
type
b
begin
michael
addit
hydrazin
n
ndimethylacrylamid
time
protect
central
nitrogen
tertbutoxycarbonyl
group
gener
scheme
reaction
benzyl
chloroform
aord
deprotect
acid
liber
secondari
nitrogen
permit
acyl
varieti
protect
amino
acid
peptid
condens
aord
azaglutamin
deriv
rel
instabl
intermedi
free
basic
nitrogen
solubl
scheme
problem
nacetyllleucinyllalanyllalanin
tripeptid
prove
advantag
form
tetrapeptid
analogu
via
two
stage
coupl
thu
compound
deprotect
coupl
dipeptid
nacetyllleucinyllalanin
give
respect
hydrogenolyt
remov
cbz
group
follow
immedi
reaction
onitrosulfenyl
chlorid
yield
correspond
azaglutamin
sulfenamid
deriv
respect
compound
hydrazo
nitrogen
nomin
posit
substrat
p
carbonyl
sulfur
p
h
nitrogen
site
assay
type
b
compound
ie
inhibit
hav
proteinas
show
better
bind
type
analogu
presum
frame
shift
peptid
backbon
allow
bulki
onitrophenyl
group
occupi
site
p
h
bind
region
enzym
activ
site
howev
substanc
still
give
modest
level
inhibit
ic
valu
mm
except
tetrapeptid
analogu
initi
ic
ca
mm
electrospray
mass
spectrometri
hav
enzym
inhibit
prolong
period
h
show
format
enzymenitrophenyl
protein
molecular
ion
peak
shift
higher
mass
unit
h
rel
poor
competit
substrat
may
due
unfavor
interact
aromat
portion
inhibitor
enzym
activ
site
although
sulfenamid
azapeptid
potent
inhibitor
hav
proteinas
peptid
aldehyd
keton
repres
new
structur
type
reason
access
stabl
may
use
inhibit
cystein
proteinas
although
addit
thiol
ad
assay
mixtur
present
studi
possibl
reaction
compound
b
c
free
thiol
vivo
remov
onitrophenylsulfenyl
group
extran
thiol
gener
requir
harsh
condit
includ
strong
acid
eg
ptoluenesulfon
acid
high
concentr
thiol
cell
cultur
studi
could
help
determin
whether
sulfenamid
function
like
benign
stabl
vivo
peptid
halomethyl
carbonyl
compound
potent
inactiv
proteinas
mention
bromoacetyl
azaglutamin
deriv
report
irrevers
inhibitor
hrv
enzym
avail
precursor
aza
analogu
preced
work
encourag
construct
chloroacetyl
bromoacetyl
azaglutamin
deriv
respect
scheme
thu
reduct
deprotect
scheme
follow
immedi
acyl
chloroacetyl
chlorid
bromoacetyl
bromid
aord
target
compound
directli
expect
show
potent
timedepend
irrevers
inhibit
hav
proteinas
rate
constant
k
ob
respect
electrospray
mass
spectrometri
enzymeinhibitor
complex
show
addit
mass
unit
molecular
ion
suggest
case
displac
halogen
activ
site
thiol
accord
reaction
hav
keton
studi
nmr
spectrometri
well
displac
halogen
iodoacetyl
peptid
activ
site
thiol
compound
somewhat
less
activ
hav
enzym
hrv
proteinas
k
inact
k
valu
reason
uncertain
like
dierenc
proxim
subsit
interact
p
p
two
enzym
cognat
inhibitor
possibl
presenc
two
methyl
group
glutamin
analogu
side
chain
also
eect
moreov
clear
recognit
peptid
moieti
inhibitor
crucial
inher
reactiv
compound
niodoacetamid
second
order
rate
constant
inactiv
conclus
present
work
provid
synthet
access
four
type
aza
amino
acid
peptid
analogu
although
show
bind
structur
type
weak
initi
inhibitori
activ
structur
type
b
c
toward
hepat
viru
proteinas
haloacetyl
azaglutamin
tetrapeptid
well
sulfenamid
azaglutamin
deriv
irrevers
react
activ
site
thiol
unreason
expect
substrat
analogu
may
potent
use
type
cystein
proteinas
current
studi
type
inhibitor
picornavir
proteinas
report
shortli
gener
procedur
instrument
previous
describ
prepar
assay
hav
protein
without
inhibitor
done
previous
report
puriti
enzym
sampl
greater
determin
sdspage
analysi
proteinas
concentr
determin
spectrophotometr
use
mg
ml
enzym
activ
monitor
use
trinitrobenzen
sulfon
tnb
assay
previous
describ
reaction
mixtur
incub
reaction
buer
c
aliquot
ml
remov
reaction
mixtur
time
interv
peptid
hydrolysi
quench
ml
sodium
borat
ph
solut
ml
freshli
prepar
tnb
ward
hill
sodium
borat
solut
ad
quench
reaction
mixtur
incub
min
c
color
stabil
ad
ml
mm
na
kh
po
concentr
free
amin
gener
peptid
hydrolysi
determin
measur
absorb
nm
use
microtitr
plate
reader
biorad
richmond
ca
proteinas
inactiv
quantit
evalu
progress
curv
analysi
previous
describ
extent
peptid
proteolysi
releas
aamino
group
monitor
use
tnb
assay
concentr
potenti
inhibitor
vari
mm
substrat
acelrtqsfsamid
concentr
mm
proteinas
mutant
concentr
mm
enzym
dialyz
reaction
buer
remov
dtt
immedi
prior
use
reaction
initi
enzym
absorb
convert
mmole
product
use
glycin
standard
curv
determin
perform
triplic
dierent
enzym
inhibitor
prepar
progress
curv
use
least
squar
nonlinear
regress
analysi
use
mac
curv
fit
k
raner
n
initi
veloc
k
appar
order
rate
constant
k
ob
inactiv
process
weight
averag
paramet
estim
minimum
three
individu
experi
use
calcul
report
rate
constant
gener
peptid
synthesi
procedur
describ
earlier
employ
rainin
solidphas
peptid
synthes
use
standard
fmoc
chemistri
wang
resin
peptid
reversephas
hplc
cm
vydac
min
linear
gradient
tfawat
ad
tfaacetonitril
peptid
structur
nmr
mass
spectrometri
case
restrict
rotat
around
amid
bond
gener
conform
detect
nmr
spectrometri
high
temperatur
studi
done
demonstr
equilibria
coalesc
reson
mass
spectrometri
enzymeinhibitor
complex
employ
instrument
methodolog
preced
public
triethylamin
ml
mmol
ad
dropwis
stir
solut
amin
salt
g
mmol
dri
ch
cl
ml
argon
c
mixtur
stir
c
min
methanesulfonyl
chlorid
ml
mmol
triethylamin
ml
mmol
ad
dropwis
reaction
mixtur
stir
c
h
concentr
vacuo
etoac
ml
ad
residu
precipit
remov
wash
water
ml
satur
aq
nahco
ml
brine
ml
dri
na
solvent
remov
vacuo
give
oil
chromatographi
ethyl
acet
gave
sulfonamid
g
oil
ir
ch
propanamid
procedur
prepar
employ
react
amin
salt
g
mmol
obtain
deprotect
bocbalanin
dimethylamid
triethylamin
ml
mmol
ptoluenesulfonyl
chlorid
g
mmol
give
previous
report
stir
solut
sulfonamid
g
mmol
anhydr
dmf
ml
argon
c
ad
nah
dispers
miner
oil
g
mmol
small
portion
mixtur
stir
c
addit
min
result
yellow
anion
solut
ad
dropwis
min
period
stir
solut
bromo
compound
g
mmol
dmf
ml
h
room
temperatur
solvent
remov
vacuo
residu
dissolv
ch
cl
wash
aq
hcl
ml
aq
nahco
ml
brine
ml
organ
phase
dri
na
concentr
vacuo
give
oil
procedur
use
prepar
employ
condens
sulfonamid
g
mmol
bromomethyl
keton
procedur
use
prepar
adapt
convert
ncbz
sulfonamid
g
mmol
palladium
charcoal
mg
solut
dipeptid
acleualaoh
g
mmol
dri
thf
ml
argon
c
treat
ethyl
chloroform
ml
mmol
triethylamin
ml
mmol
stir
min
solut
sulfonamido
amin
hydrochlorid
g
mmol
thf
ml
triethylamin
ml
mmol
ad
reaction
mixtur
stir
min
allow
warm
room
temperatur
stir
overnight
mixtur
ad
etoac
ml
organ
phase
wash
satur
aq
nahco
ml
brine
ml
dri
na
concentr
vacuo
give
crude
product
hplc
linear
gradient
elut
ms
fab
mh
procedur
use
prepar
use
condens
dipeptid
acleualaoh
g
mmol
sulfonamido
amin
hydrochlorid
g
mmol
presenc
ethyl
chloroform
ml
mmol
triethylamin
ml
mmol
hplc
linear
gradient
elut
min
acetonitril
water
r
min
gave
titl
compound
g
solid
spectral
character
show
mixtur
conform
n
ndimethylacrylamid
g
mmol
ad
dropwis
solut
hydrazin
monohydr
g
mmol
meoh
ml
reaction
mixtur
stir
room
temperatur
h
dilut
meoh
ml
dri
na
concentr
vacua
give
crude
n
dimethyl
propanamid
g
stir
solut
compound
g
mmol
mixtur
diethyl
ether
ml
water
ml
n
naoh
ml
cool
icebath
benzyl
chloroform
ml
mmol
ad
stir
continu
icebath
h
precipit
concentr
vacuo
ml
extract
ethyl
acet
ml
combin
organ
extract
wash
brine
ml
dri
na
solvent
concentr
vacua
give
oil
chromatographi
ethyl
acet
methanol
gave
desir
g
solut
tripeptid
acleualaalaoh
g
mmol
cbz
hydrazino
deriv
g
mmol
benzotriazolylnoxytri
dimethylamino
phosphonium
bop
g
mmol
dmf
ml
ad
triethylamin
ml
mmol
mixtur
stir
room
temperatur
h
concentr
vacuo
give
oil
solut
cbz
deriv
mg
mmol
methanol
ml
argon
ad
palladium
charcoal
catalyst
mg
mixtur
stir
atmospher
hydrogen
ga
absorpt
ceas
catalyst
remov
column
celit
concentr
vacuo
give
unstabl
deprotect
hydrazin
mg
quantit
stir
solut
crude
materi
mg
mmol
onitrophenylsulfenyl
chlorid
mg
mmol
dmf
ml
argon
c
ad
triethylamin
ml
mmol
min
c
reaction
mixtur
allow
warm
room
temperatur
stir
h
solut
concentr
vacuo
hplc
linear
gradient
elut
min
acetonitril
water
r
min
gave
titl
compound
mg
yellow
powder
spectral
character
indic
mixtur
conform
conform
conform
b
n
h
n
ndimethylamino
h
oxopropyl
n
p
methylphenylsulfonyl
hydrochlo
ride
n
benzyloxycarbonyl
hydrazino
n
n
dimethyl
propanamid
propanamid
stir
solut
crude
n
dimethyl
propanamid
g
mmol
obtain
prepar
mixtur
dioxan
ml
water
ml
n
naoh
ml
cool
icebath
ditertbutyl
pyrocarbon
g
mmol
ad
stir
continu
room
temperatur
h
precipit
concentr
vacuo
ml
extract
ethyl
acet
ml
combin
organ
extract
wash
brine
ml
dri
na
concentr
vacuo
give
oil
suspens
bocpropanamid
g
mmol
anhydr
potassium
carbon
g
mmol
dri
thf
ml
ad
benzyl
chloroform
g
mmol
vigor
stir
mixtur
heat
c
h
precipit
khco
k
co
remov
concentr
vacuo
residu
dissolv
ethyl
acet
ml
wash
n
nahco
ml
water
ml
brine
ml
dri
na
concentr
vacuo
give
oil
n
acetyldalanyl
n
benzyloxycarbonyl
hydrazino
n
n
dimethyl
propanamid
stir
solut
boc
deriv
g
mmol
dri
ch
cl
ml
argon
ad
acid
ml
solut
stir
room
temperatur
h
concentr
vacuo
toluen
ml
ad
mixtur
concentr
vacuo
residu
dri
vacuo
overnight
give
crude
unstabl
hydrazino
compound
dissolv
dri
thf
ml
triethylamin
ml
mmol
ad
form
amin
solut
solut
nacetyldalanin
g
mmol
dri
thf
ml
cool
c
stir
argon
triethylamin
ml
mmol
ethyl
chloroform
ml
mmol
ad
mixtur
stir
min
c
amin
solut
ad
min
c
reaction
mixtur
allow
warm
room
temperatur
stir
h
precipit
concentr
vacuo
residu
dissolv
ethyl
acet
ml
wash
said
aq
nh
cl
ml
n
nahco
ml
brine
ml
dri
na
concentr
vacua
give
oil
procedur
use
prepar
adapt
prepar
salt
g
mmol
condens
nacetyllalanin
g
mmol
give
g
gum
ir
ch
n
tertbutyloxycarbonyllalanyl
n
benzyloxycarbonyl
hydrazino
n
n
dimethyl
propanamid
procedur
prepar
adapt
prepar
condens
salt
g
mmol
ntboclalanin
g
mmol
give
g
colorless
oil
ir
ch
n
tertbutyloxycarbonyl
alanyl
n
benzyloxycarbonyl
hydrazino
n
n
dimethyl
propanamid
procedur
use
prepar
adapt
prepar
convert
salt
g
mmol
ntbocbalanin
g
mmol
g
oil
ir
ch
n
acetyllleucyllalanyllalanyl
n
benzyloxycarbonyl
hydrazino
n
n
dimethyl
propanamid
procedur
prepar
adapt
convert
g
mmol
acleualaoh
mg
mmol
crude
product
hplc
linear
gradient
elut
min
acetonitril
water
r
min
give
g
white
solid
mp
c
ir
ch
